Art

J-GLOBAL ID：202302272509889276   Reference number：23A1723488

How to use COVID-19 antiviral drugs in patients with chronic kidney disease

慢性腎臓病患者におけるCOVID-19抗ウイルス薬の使用法【JST・京大機械翻訳】

Author (5)： Kale Ajinath (1Laboratory of Molecular Pharmacology, Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Rajasthan, India) ,  Shelke Vishwadeep (1Laboratory of Molecular Pharmacology, Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Rajasthan, India) ,  Dagar Neha (1Laboratory of Molecular Pharmacology, Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Rajasthan, India) ,  Anders Hans-Joachim (2Division of Nephrology, Department of Internal Medicine IV, Hospital of the Ludwig Maximilians University Munich, Munich, Germany.) ,  Gaikwad Anil Bhanudas (1Laboratory of Molecular Pharmacology, Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Rajasthan, India)
Material： Frontiers in Pharmacology (Web)
Volume： 14  Page： 1053814  Publication year： 2023 
JST Material Number： U7091A  ISSN： 1663-9812  Document type： Article
Article type： 文献レビュー  Country of issue： Switzerland (CHE)  Language： ENGLISH (EN)

Abstract/Point： Antiviral drugs such as Remdes...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=23A1723488&from=J-GLOBAL&jstjournalNo=U7091A") }}

Thesaurus term： sensitivity ,  *antiviral drug ,  mortality ,  side effect ,  *kidney disease ,  clinical trial ,  *patient ,  monoclonal antibody ,  complication ,  risk factor ,  pharmacodynamics ,  *chronic kidney disease
Semi thesaurus term： 発症リスク ,  急性腎障害 ,  腎機能障害 , 【Automatic Indexing@JST】

Author keywords (7)： COVID-19 ,  antivirals ,  chronic kidney disease ,  clinical trials ,  pharmacokinetics ,  pharmacodynamics ,  monoclonal antibodies

JST classification (4)： Urogenital diseases  (GM03000L) ,  Urologenital system diagnosis  (GM02000E) ,  Treatment for metabolic diseases,nutritional diseases.  (GD05030F) ,  Clinical medicine on urogenital system in general  (GM01030E)

Reference (138)：

• AbbassS., KamalE., SalamaM., SalmanT., SabryA., Abdel-RazekW., et al (2021). Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial. J. Med. Virology 93 (12), 6750-6759. doi: 10.1002/jmv.27264
• AbdallaS., ElgassimL., RustomF., OthmanM. (2020). Acute kidney injury caused by darunavir in a patient with COVID-19: A case report. Open J. Nephrol. 10 (4), 375-382. doi: 10.4236/ojneph.2020.104037
• AkhilM. S., KirushnanB., MartinM., ArumugamK., Ganesh PrasadN. K., RavichandranR. (2018). Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study. Nephrology 23 (5), 446-452. doi: 10.1111/nep.13050
• BauschD. G., HadiC. M., KhanS. H., LertoraJ. J. L. (2010). Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin. Infect. Dis. 51 (12), 1435-1441. doi: 10.1086/657315
• BeigelJ. H., TomashekK. M., DoddL. E., MehtaA. K., ZingmanB. S., KalilA. C., et al (2020). Remdesivir for the treatment of covid-19 - final report. N. Engl. J. Med. 383 (19), 1813-1826. doi: 10.1056/NEJMoa2007764

Terms in the title (4)： 慢性 ,  腎臓病患者 ,  抗ウイルス薬 ,  使用法